(RTTNews) - InflaRx N.V. (IFRX) said Thursday that it has received a corrected advice letter from the U.S. Food and Drug Administration regarding its Phase III program with vilobelimab for the ...
Jan 30 (Reuters) - Shares of Corcept ‌Therapeutics fell 16% on Friday after ‌a corrected "complete response letter" from the U.S. Food and Drug Administration showed the agency had warned the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results